News
Zacks Investment Research on MSN16h
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory IndicationsSanofi SNY announced preliminary data from the phase II TIDE-Asthma study, which evaluated its anti-OX40L mAb, amlitelimab, for treating adults with moderate-to-severe asthma. The company also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback